1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome e-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

ALL - 589

Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome e-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

Elias Jabbour

Poster Presenter: Elias Jabbour

Thumbnail for Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

ALL - 741

Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Kezhi Huang

Poster Presenter: Kezhi Huang

AML - 526

Operational Barriers to Precision Genomic Testing in Hematologic Malignancies: A Qualitative Study

Summiya Nasim

Poster Presenter: Summiya Nasim

Thumbnail for Opportunistic Infections During Adult CAR-T Hospitalizations in the United States: A National Inpatient Sample (NIS) Analysis, 2018-2022

CT - 187

Opportunistic Infections During Adult CAR-T Hospitalizations in the United States: A National Inpatient Sample (NIS) Analysis, 2018-2022

Sheikh Abdullah

Poster Presenter: Sheikh Abdullah

Thumbnail for Opportunistic Neurologic Infections With CD3-Engaging Bispecific Antibodies in Hematologic Malignancies: A FAERS Disproportionality Analysis

MM - 1497

Opportunistic Neurologic Infections With CD3-Engaging Bispecific Antibodies in Hematologic Malignancies: A FAERS Disproportionality Analysis

B?sranur Yilmaz

Poster Presenter: B?sranur Yilmaz

$Thumbnail for OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)$

MM - 1078

OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Thomas S. Lin

Poster Presenter: Thomas S. Lin

Video

CT - 1389

Optimal Hemoglobin Thresholds in Hematologic Malignancies: Comparative Evidence for Restrictive and Liberal Transfusion

Hem Prajapati

Poster Presenter: Hem Prajapati

Thumbnail for Optimizing Donor Age for Allogeneic Transplant in Acute Lymphoblastic Leukemia in the Era of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Prophylaxis

ALL - 1394

Optimizing Donor Age for Allogeneic Transplant in Acute Lymphoblastic Leukemia in the Era of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Prophylaxis

John Behman

Poster Presenter: John Behman

Thumbnail for Optimizing Low-Intensity Therapeutic Strategies in Older Acute Myeloid Leukemia: A Systematic Review and Network Meta-Analysis

AML - 811

Optimizing Low-Intensity Therapeutic Strategies in Older Acute Myeloid Leukemia: A Systematic Review and Network Meta-Analysis

Ahmad Shafi Antar

Poster Presenter: Ahmad Shafi Antar